Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
Int J Nephrol Renovasc Dis. 2023 Dec 22;16:281-291. doi: 10.2147/IJNRD.S430377. eCollection 2023.ABSTRACTImmunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It is characterized by the mesangial deposition of IgA-containing immune complexes, triggering damage to the glomerular filtration barrier that is amplified by the tandem action of endothelin-1 and angiotensin II at their receptors. Proteinuria and progressive glomerular damage cause loss of kidney function in up to 50% of patients within 10-20 years. The risk of progression is strongly associated with persistent proteinuria (&g...
Source: International Journal of Nephrology and Renovascular Disease - December 27, 2023 Category: Urology & Nephrology Authors: Kirk N Campbell Si ân Griffin Howard Trachtman Rob Geletka Muh Geot Wong Source Type: research
Irbesartan eases lipopolysaccharide-induced lung injury < em > In Vitro < /em > and < em > In Vivo < /em >
Chin J Physiol. 2023 Nov-Dec;66(6):516-525. doi: 10.4103/cjop.CJOP-D-23-00131.ABSTRACTAcute lung injury (ALI) is classified as a devastating pulmonary disorder contributing to significant incidence and fatality rate. Irbesartan (IRB) is an angiotensin II receptor blocker that has been proposed to protect against oleic acid-induced ALI. To this end, the current study is concentrated on ascertaining the role of IRB in ALI and figuring out the probable action mechanism. First, cell counting kit-8 (CCK-8) appraised the viability of human pulmonary microvascular endothelial cells (HPMVECs) exposed to ascending concentrations of...
Source: The Chinese Journal of Physiology - December 27, 2023 Category: Physiology Authors: Zhongyuan Zhang Wei Wang Source Type: research
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
Int J Nephrol Renovasc Dis. 2023 Dec 22;16:281-291. doi: 10.2147/IJNRD.S430377. eCollection 2023.ABSTRACTImmunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It is characterized by the mesangial deposition of IgA-containing immune complexes, triggering damage to the glomerular filtration barrier that is amplified by the tandem action of endothelin-1 and angiotensin II at their receptors. Proteinuria and progressive glomerular damage cause loss of kidney function in up to 50% of patients within 10-20 years. The risk of progression is strongly associated with persistent proteinuria (&g...
Source: International Journal of Nephrology and Renovascular Disease - December 27, 2023 Category: Urology & Nephrology Authors: Kirk N Campbell Si ân Griffin Howard Trachtman Rob Geletka Muh Geot Wong Source Type: research
Irbesartan eases lipopolysaccharide-induced lung injury < em > In Vitro < /em > and < em > In Vivo < /em >
Chin J Physiol. 2023 Nov-Dec;66(6):516-525. doi: 10.4103/cjop.CJOP-D-23-00131.ABSTRACTAcute lung injury (ALI) is classified as a devastating pulmonary disorder contributing to significant incidence and fatality rate. Irbesartan (IRB) is an angiotensin II receptor blocker that has been proposed to protect against oleic acid-induced ALI. To this end, the current study is concentrated on ascertaining the role of IRB in ALI and figuring out the probable action mechanism. First, cell counting kit-8 (CCK-8) appraised the viability of human pulmonary microvascular endothelial cells (HPMVECs) exposed to ascending concentrations of...
Source: The Chinese Journal of Physiology - December 27, 2023 Category: Physiology Authors: Zhongyuan Zhang Wei Wang Source Type: research
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
Int J Nephrol Renovasc Dis. 2023 Dec 22;16:281-291. doi: 10.2147/IJNRD.S430377. eCollection 2023.ABSTRACTImmunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It is characterized by the mesangial deposition of IgA-containing immune complexes, triggering damage to the glomerular filtration barrier that is amplified by the tandem action of endothelin-1 and angiotensin II at their receptors. Proteinuria and progressive glomerular damage cause loss of kidney function in up to 50% of patients within 10-20 years. The risk of progression is strongly associated with persistent proteinuria (&g...
Source: International Journal of Nephrology and Renovascular Disease - December 27, 2023 Category: Urology & Nephrology Authors: Kirk N Campbell Si ân Griffin Howard Trachtman Rob Geletka Muh Geot Wong Source Type: research
Irbesartan eases lipopolysaccharide-induced lung injury < em > In Vitro < /em > and < em > In Vivo < /em >
Chin J Physiol. 2023 Nov-Dec;66(6):516-525. doi: 10.4103/cjop.CJOP-D-23-00131.ABSTRACTAcute lung injury (ALI) is classified as a devastating pulmonary disorder contributing to significant incidence and fatality rate. Irbesartan (IRB) is an angiotensin II receptor blocker that has been proposed to protect against oleic acid-induced ALI. To this end, the current study is concentrated on ascertaining the role of IRB in ALI and figuring out the probable action mechanism. First, cell counting kit-8 (CCK-8) appraised the viability of human pulmonary microvascular endothelial cells (HPMVECs) exposed to ascending concentrations of...
Source: The Chinese Journal of Physiology - December 27, 2023 Category: Physiology Authors: Zhongyuan Zhang Wei Wang Source Type: research
Practical Considerations for the Use of Sparsentan in the Treatment of Patients with IgAN in Clinical Practice
Int J Nephrol Renovasc Dis. 2023 Dec 22;16:281-291. doi: 10.2147/IJNRD.S430377. eCollection 2023.ABSTRACTImmunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. It is characterized by the mesangial deposition of IgA-containing immune complexes, triggering damage to the glomerular filtration barrier that is amplified by the tandem action of endothelin-1 and angiotensin II at their receptors. Proteinuria and progressive glomerular damage cause loss of kidney function in up to 50% of patients within 10-20 years. The risk of progression is strongly associated with persistent proteinuria (&g...
Source: International Journal of Nephrology and Renovascular Disease - December 27, 2023 Category: Urology & Nephrology Authors: Kirk N Campbell Si ân Griffin Howard Trachtman Rob Geletka Muh Geot Wong Source Type: research
Irbesartan eases lipopolysaccharide-induced lung injury < em > In Vitro < /em > and < em > In Vivo < /em >
Chin J Physiol. 2023 Nov-Dec;66(6):516-525. doi: 10.4103/cjop.CJOP-D-23-00131.ABSTRACTAcute lung injury (ALI) is classified as a devastating pulmonary disorder contributing to significant incidence and fatality rate. Irbesartan (IRB) is an angiotensin II receptor blocker that has been proposed to protect against oleic acid-induced ALI. To this end, the current study is concentrated on ascertaining the role of IRB in ALI and figuring out the probable action mechanism. First, cell counting kit-8 (CCK-8) appraised the viability of human pulmonary microvascular endothelial cells (HPMVECs) exposed to ascending concentrations of...
Source: The Chinese Journal of Physiology - December 27, 2023 Category: Physiology Authors: Zhongyuan Zhang Wei Wang Source Type: research
